Blockade of TIGIT-PVR Axis can Treat Breast Cancer

Autores

  • Ana Hernandez Garcia University of Kansas, School of Professional Studies, Biotechnology

DOI:

https://doi.org/10.17161/mjusc.v1i1.18570

Palavras-chave:

TIGIT, Checkpoint Inhibitor, Cancer, Breast, PVR, immunology

Resumo

This review covers the identification and application of anti-TIGIT antibodies as checkpoint inhibitors for the treatment of triple-negative breast cancers. The original article, Targeting the TIGIT-PVR Immune Checkpoint Axis as Novel Therapeutic Option in Breast Cancer, was published by Stamm et al. in Oncoimmunology in October of 2019.

Cover of issue 1 of the Midwestern Journal of Undergraduate Sciences showing an illustration of checkpoint inhibitors

Downloads

Publicado

2022-10-03

Edição

v. 1 n. 1 (2022)

Seção

Reviews

Licença

Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.

© The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. 

Como Citar

Hernandez Garcia, A. (2022). Blockade of TIGIT-PVR Axis can Treat Breast Cancer. Midwestern Journal of Undergraduate Sciences, 1(1), 5. https://doi.org/10.17161/mjusc.v1i1.18570